Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz

RefinitivMenos de 1 minuto de lectura

Vanda Pharmaceuticals Inc VNDA:

VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Inicie sesión o cree una cuenta gratuita y permanente para leer esta noticia